Skip to content
thestock.space

On 6 Nov 2026, BDH Industries was priced at ₹432.00, or 21.2× trailing earnings, against an industry P/E of 28.7×, and the shares are 29% below their 52-week high. It earns ROCE of 16% and ROE of 15%, and sales and net profit grew 8.5% and 9.6% a year over 3 years. It has almost no debt, and its dividend yield is 1.2%. It is a small-cap company with a market cap of ₹249 Cr, ranked 89th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 3.3% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹445.00
Day high
₹447.20
Day low
₹411.00
Prev. close
₹426.15
Volume
758

Health check

2 good · 2 fair · 2 to check
  • ReturnsBehind

    +3.3% over a year, better than 1 of 7 peers.

  • Price tagCheaper

    P/E 21.2 vs industry 28.7.

  • GrowthSlow

    Sales +8.5%, profit +9.6% a year over 3 years.

  • ProfitabilityAverage

    ROCE 16.4% vs peer median 17.9%.

  • Balance sheetFair

    Practically debt-free, Piotroski 5 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹249 Cr, #89 of 154 in its industry by size.

Defensive

Beta 0.28 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹100 Cr · profit ₹12 Cr
Market cap
₹249 Cr
Small cap
P/E
21.2
Industry 28.7
Price to book
3.23
Peers 4.99
Dividend yield
1.16%
ROE
14.8%
Peers 14.7%
ROCE
16.4%
Peers 17.9%
Debt to equity
0.03
Debt ₹2.02 Cr
EPS (TTM)
₹20.34
OPM (TTM)
15.3%
Net margin 11.7%
Sales growth
+20.2%
Latest quarter vs a year ago
Profit growth
+49.1%
Latest quarter vs a year ago
Price to sales
2.49
EV/EBITDA 14.5

Strengths and risks

Strengths

  • Practically debt-free.
  • Quarterly profit up 49.1% on a year ago.
  • Quarterly sales up 20.2% on a year ago.
  • P/E of 21.2 against an industry P/E of 28.7.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About BDH Industries

BDH Industries Limited engages in the manufacture and sale of therapeutic formulations for pharmaceuticals in India and Internationally. The company operates in two segments, Pharmaceuticals and Renewable Energy. It offers finished pharmaceuticals products, such as analgesic antipyretic, analgesic balm, antacids, acaricide, anthelmintics, antiprotozoal, aniti-glaucoma, antiseptics, anti-psychotics, anti-tuberculosis, anti-allergics, anti-tussive,…

Headquarters
Mumbai
Employees
95
Sector
Healthcare
ISIN
INE278D01018
Website
bdhind.com

Price range

52 weeks

₹340.15₹610.00

Today

₹411.00₹447.20
Avg volume (3M)
1.3K
1-year return
plus 3.3%
From 52-week high
minus 29.2%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
BDHBDH Industries432.00plus 1.37%24921.23.2316.4%14.8%15.3%8.5%9.6%1.16%plus 3.3%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
18.61929.32922.4
16.515.625.124.818.9
2.13.34.24.23.5
11.4%17.5%14.4%14.5%15.5%
0.50.60.50.60.4
00000
0.20.20.20.20.2
2.43.64.54.63.7
25.2%27.9%23.0%37.3%26.3%
1.82.63.52.92.7
3.174.556.065.004.73

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+8.5%
Profit CAGR 3Y
+9.6%
EPS CAGR 3Y
+9.6%
ROE
14.8%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
73.884.864.994.3
–+14.9%minus 23.5%+45.3%
62.972.453.380.4
1112.411.613.9
14.8%14.6%17.9%14.7%
0.81.61.82.2
0.20.20.10.1
0.60.60.90.9
11.113.312.515.2
25.9%25.5%25.6%28.8%
8.29.99.310.8
–+20.3%minus 6.0%+16.6%
14.2517.1416.1118.78

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
5.85.85.85.8
48.956.46371.3
4.88.712
20.522.617.220.1
8093.486.999.1
1920.419.718.8
0.40.40.40.4
25.424.630.729
35.348.136.250.9
8093.486.999.1

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
6.3−1.914.8−2.4
0.5−0.31.62.2
0.41.4−10.4−1.6
7.1−0.86−1.8
−0−1.9−0.2−0
6.3−3.814.6−2.4
−2.1−2.3−2.6−2.6

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you